Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure

Background As a mediator of ECM homeostasis, connective tissue growth factor (CTGF) appears to be involved in adverse structural remodeling processes in the heart. However, the diagnostic and prognostic value of CTGF levels in acute heart failure (AHF) in addition to natriuretic peptide testing has...

Full description

Saved in:
Bibliographic Details
Published in:Clinical research in cardiology 2014-02, Vol.103 (2), p.107-116
Main Authors: Behnes, Michael, Brueckmann, Martina, Lang, Siegfried, Weiß, Christel, Ahmad-Nejad, Parviz, Neumaier, Michael, Borggrefe, Martin, Hoffmann, Ursula
Format: Article
Language:English
Subjects:
Aged
Area Under Curve
Biomarkers - blood
Cardiology
Connective Tissue Growth Factor - blood
Female
Germany
Heart Failure - blood
Heart Failure - diagnosis
Heart Failure - therapy
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Natriuretic Peptide, Brain - blood
Original Paper
Peptide Fragments - blood
Predictive Value of Tests
Prognosis
Prospective Studies
Risk Assessment
Risk Factors
ROC Curve
Severity of Illness Index
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background As a mediator of ECM homeostasis, connective tissue growth factor (CTGF) appears to be involved in adverse structural remodeling processes in the heart. However, the diagnostic and prognostic value of CTGF levels in acute heart failure (AHF) in addition to natriuretic peptide testing has not yet been evaluated. Methods and results A total of 212 patients presenting with acute dyspnea and/or peripheral edema to the Emergency Department were evaluated. CTGF and NT-proBNP plasma levels were measured at the initial presentation. All patients were followed up to 1 and 5 years. The first endpoint tested was the diagnostic non-inferiority of combined CTGF plus NT-proBNP compared to NT-proBNP alone for AHF diagnosis. Afterwards, the additional diagnostic value of CTGF plus NT-proBNP was tested. CTGF levels were higher in NYHA class III/IV and AHA/ACC class C/D patients compared to lower class patients ( p  = 0.04). Patients with HFREF revealed highest CTGF levels (median 93.3 pg/ml, IQR 18.2–972 pg/ml, n  = 48) compared to patients with a normal heart function (i.e., without HFREF and HFPEF) (median 25.9, IQR 
ISSN:1861-0684
1861-0692
DOI:10.1007/s00392-013-0626-6